ATE553123T1 - Wachstumsfaktormutanten mit hoher aktivität - Google Patents

Wachstumsfaktormutanten mit hoher aktivität

Info

Publication number
ATE553123T1
ATE553123T1 AT06818642T AT06818642T ATE553123T1 AT E553123 T1 ATE553123 T1 AT E553123T1 AT 06818642 T AT06818642 T AT 06818642T AT 06818642 T AT06818642 T AT 06818642T AT E553123 T1 ATE553123 T1 AT E553123T1
Authority
AT
Austria
Prior art keywords
growth factor
high activity
factor mutants
mutants
biological activity
Prior art date
Application number
AT06818642T
Other languages
English (en)
Inventor
Jens Pohl
Frank Ploeger
Michael Kruse
Original Assignee
Bioph Biotech Entw Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37628151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE553123(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioph Biotech Entw Pharm Gmbh filed Critical Bioph Biotech Entw Pharm Gmbh
Application granted granted Critical
Publication of ATE553123T1 publication Critical patent/ATE553123T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
AT06818642T 2005-11-18 2006-11-17 Wachstumsfaktormutanten mit hoher aktivität ATE553123T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025261 2005-11-18
PCT/EP2006/011074 WO2007057212A1 (en) 2005-11-18 2006-11-17 High activity growth factor mutants

Publications (1)

Publication Number Publication Date
ATE553123T1 true ATE553123T1 (de) 2012-04-15

Family

ID=37628151

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06818642T ATE553123T1 (de) 2005-11-18 2006-11-17 Wachstumsfaktormutanten mit hoher aktivität

Country Status (13)

Country Link
US (3) US8188226B2 (de)
EP (1) EP1948689B1 (de)
JP (1) JP5654730B2 (de)
AT (1) ATE553123T1 (de)
AU (1) AU2006314713B2 (de)
CA (1) CA2627370C (de)
CY (1) CY1112877T1 (de)
DK (1) DK1948689T3 (de)
ES (1) ES2382464T3 (de)
PL (1) PL1948689T3 (de)
PT (1) PT1948689E (de)
SI (1) SI1948689T1 (de)
WO (1) WO2007057212A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4938628B2 (ja) * 2007-10-29 2012-05-23 Ｈｏｙａ株式会社 リン酸カルシウム系化合物、リン酸カルシウム系化合物／コラーゲン複合体及びリン酸カルシウム系細胞培養担体に付着又は吸着したエンドトキシンの抽出方法及び定量方法
EP2300610A1 (de) * 2008-06-09 2011-03-30 Wyeth LLC Neue bmp-12-verwandte proteine und herstellungsverfahren dafür
EP2602264A1 (de) 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5-Mutant zur Induzierung der Knorpelbildung
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
DE19525416A1 (de) 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
WO1994015949A1 (en) 1993-01-12 1994-07-21 Johns Hopkins University School Of Medicine Growth differentiation factor-5
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
ES2255059T3 (es) * 1993-12-07 2006-06-16 Genetics Institute, Llc Bmp-12, bmp-13 y composiciones suyas inductoras de tendon.
AU1120295A (en) 1994-11-07 1996-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cartilage-derived morphogenetic proteins
PL186518B1 (pl) 1995-04-19 2004-01-30 Bioph Biotech Entw Pharm Gmbh Białko, kompozycja farmaceutyczna i sposób wytwarzania białka
JPH0931098A (ja) 1995-07-24 1997-02-04 Hoechst Japan Ltd 新規なタンパク質ｈｍｗヒトｍｐ５２
US5758328A (en) 1996-02-22 1998-05-26 Giovannoli; Joseph Computerized quotation system and method
JPH11335398A (ja) 1998-05-22 1999-12-07 Hoechst Marion Roussel Kk 新規な骨誘導活性を有する単量体蛋白質およびそれらからなる軟骨・骨疾患の予防および治療薬
EP1074620A1 (de) 1999-08-06 2001-02-07 HyGene AG Monomer Protein der TGF-beta Familie
CA2301693A1 (en) * 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
AU778998B2 (en) * 1998-09-22 2004-12-23 University Of Maryland At Baltimore Cystine knot growth factor mutants
JP2000119192A (ja) * 1998-10-09 2000-04-25 Aventis Pharma Ltd 骨誘導因子アンタゴニスト活性を有する成熟型蛋白質
US5989863A (en) * 1998-10-14 1999-11-23 Incyte Pharmaceuticals, Inc. Human ankyrin family protein
WO2002021998A2 (en) 2000-09-12 2002-03-21 Axya Medical, Inc. Apparatus and method for securing suture to bone
EP1372698A2 (de) * 2001-03-23 2004-01-02 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Verwendung von zytokinen der tgf-beta superfamilie zur behandlung und diagnose von hauterkrankungen
US7148051B2 (en) 2004-08-16 2006-12-12 E. I. Du Pont De Nemours And Company Production of 3-hydroxycarboxylic acid using nitrilase

Also Published As

Publication number Publication date
SI1948689T1 (sl) 2012-09-28
US20080318860A1 (en) 2008-12-25
CY1112877T1 (el) 2016-04-13
JP5654730B2 (ja) 2015-01-14
CA2627370C (en) 2016-02-23
US8188226B2 (en) 2012-05-29
EP1948689B1 (de) 2012-04-11
JP2009519008A (ja) 2009-05-14
DK1948689T3 (da) 2012-07-23
US20150057223A1 (en) 2015-02-26
WO2007057212A1 (en) 2007-05-24
PT1948689E (pt) 2012-05-09
PL1948689T3 (pl) 2012-09-28
EP1948689A1 (de) 2008-07-30
ES2382464T3 (es) 2012-06-08
US20120322729A1 (en) 2012-12-20
US9200048B2 (en) 2015-12-01
AU2006314713B2 (en) 2011-10-06
AU2006314713A1 (en) 2007-05-24
CA2627370A1 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
ATE553123T1 (de) Wachstumsfaktormutanten mit hoher aktivität
MX2011011763A (es) Composiciones plaguicidas.
TW200626171A (en) Fixed dosing of HER antibodies
TW200722079A (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
GT200600174A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
GB2436983A (en) Information access with usage-driven metadata feedback
DK1809123T3 (da) Dimensionsstabilt foder til selskabsdyr med lavt indhold af carbohydrat
ATE417511T1 (de) Durchlüftete produkte mit niedrigem ph-wert
EA201001024A1 (ru) Обработка растений банана и картофеля с помощью новой противогрибковой композиции
EA200701592A1 (ru) Композиты и способы их получения и использования
ATE503767T1 (de) Herstellung eines von willenbrand faktor- präparates mit hoher spezifischer aktivität
ATE507222T1 (de) 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
DE602007006541D1 (de) Verwendung von wassergräsern als träger für erdbodenlose kultivierung und so gebildeter träger
ATE478943T1 (de) Wachstumsfaktormutanten mit verbesserter biologischer aktivität
ITRM20050556A1 (it) Struttura di ancoraggio per organismi vegetali.
ZA200800471B (en) Methods of altering poppy characteristics
DE502007003652D1 (de) Verwendung von nitratsalzen zur unterdrückung störender gerüche
RU2008136668A (ru) Пептиды, обладающие нейротропной активностью
CY1112194T1 (el) Μεθοδοι για ρυθμιση φωτοτοξικοτητας
CL2009001149A1 (es) Procedimiento de preparacion de 6,7-dihidro-tieno-[3,2-d]pirimidina-2,4-dioles 6,7 disustituidos.
RU2008125409A (ru) Ген hgfopt фактора роста гепатоцитов
ATE463499T1 (de) Silizium-harnstoff-azolide, ihre herstellung und verwendung
RS53014B (en) 4R, 5S-ENANTIOMER 2- (5-METHYL-2-OXO-4-PHENYL-PYROLIDIN-1-IL) -ACETAMIDE WITH NOOTROPIC ACTIVITY
FR2902101B1 (fr) Peptides a activite anti-proliferative